tetano
Editor, Senior Moderator
Ann Pharmacother
. 2023 Mar 31;10600280231162243.
doi: 10.1177/10600280231162243. Online ahead of print.
Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials
Akhil Deepak Vatvani[SUP] 1 [/SUP], Andree Kurniawan[SUP] 2 [/SUP], Timotius Ivan Hariyanto[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Fluvoxamine may be beneficial for the management of coronavirus disease 2019 (Covid-19) because of its effect on the sigma-1 receptor. Available evidence from randomized clinical trials (RCTs) has shown conflicting results.
Objective: This study sought to analyze the efficacy and safety of fluvoxamine as an outpatient treatment for Covid-19.
Methods: Using specific keywords, we comprehensively go through the potential articles on PubMed, Scopus, Europe PMC, and ClinicalTrials.gov sources until February 1, 2023. We collected all published clinical trials on fluvoxamine and Covid-19. We were using Review Manager 5.4 to conduct statistical analysis.
Results: We include a total of 6 trials. Our pooled analysis revealed that fluvoxamine did not offer any significant benefit when compared with placebo in reducing the risk of clinical deterioration (risk ratio [RR] = 0.83; 95% CI: 0.65-1.06, P = 0.14, I[SUP]2[/SUP] = 29%), and hospitalization (RR = 0.80; 95% CI: 0.62-1.04, P = 0.09, I[SUP]2[/SUP] = 0%) of Covid-19 outpatients. The serious adverse events did not differ significantly between the 2 groups.
Conclusions and relevance: This study indicates that although safe, fluvoxamine was not effective for outpatient treatment of Covid-19. Until more evidence can be obtained from larger RCTs, our study did not encourage the use of fluvoxamine as routine management for patients with Covid-19.
Keywords: Covid-19; SARS-CoV-2; SSRI; coronavirus disease 2019; fluvoxamine; management.
. 2023 Mar 31;10600280231162243.
doi: 10.1177/10600280231162243. Online ahead of print.
Efficacy and Safety of Fluvoxamine as Outpatient Treatment for Patients With Covid-19: A Systematic Review and Meta-analysis of Clinical Trials
Akhil Deepak Vatvani[SUP] 1 [/SUP], Andree Kurniawan[SUP] 2 [/SUP], Timotius Ivan Hariyanto[SUP] 1 [/SUP]
Affiliations
- PMID: 37002592
- DOI: 10.1177/10600280231162243
Abstract
Background: Fluvoxamine may be beneficial for the management of coronavirus disease 2019 (Covid-19) because of its effect on the sigma-1 receptor. Available evidence from randomized clinical trials (RCTs) has shown conflicting results.
Objective: This study sought to analyze the efficacy and safety of fluvoxamine as an outpatient treatment for Covid-19.
Methods: Using specific keywords, we comprehensively go through the potential articles on PubMed, Scopus, Europe PMC, and ClinicalTrials.gov sources until February 1, 2023. We collected all published clinical trials on fluvoxamine and Covid-19. We were using Review Manager 5.4 to conduct statistical analysis.
Results: We include a total of 6 trials. Our pooled analysis revealed that fluvoxamine did not offer any significant benefit when compared with placebo in reducing the risk of clinical deterioration (risk ratio [RR] = 0.83; 95% CI: 0.65-1.06, P = 0.14, I[SUP]2[/SUP] = 29%), and hospitalization (RR = 0.80; 95% CI: 0.62-1.04, P = 0.09, I[SUP]2[/SUP] = 0%) of Covid-19 outpatients. The serious adverse events did not differ significantly between the 2 groups.
Conclusions and relevance: This study indicates that although safe, fluvoxamine was not effective for outpatient treatment of Covid-19. Until more evidence can be obtained from larger RCTs, our study did not encourage the use of fluvoxamine as routine management for patients with Covid-19.
Keywords: Covid-19; SARS-CoV-2; SSRI; coronavirus disease 2019; fluvoxamine; management.